Tirzepatide is studied in research settings as a dual GIP / GLP-1 receptor agonist, with interest in incretin signaling, glycemic endpoints, food-intake models, and body-composition research
excess is excreted in urine, often causing bright yellow coloration, and no upper toxicity level has been observed)
Further, it is worth highlighting that survodutide is likely to drive the market in the near future
It is not approved for human consumption, medical treatments, or diagnostic purposes
This leads us to the question at hand
Note that L-carnitine supplementation, started on Week 1 after the 1 st S-5-HT laboratory visit, continued until the 2 nd physician visit on Week 8 when the second fatigue score value was recorded